Selected stock price target news of the day - June 17th, 2025

By: Matthew Otto

Millicom Expands South American Operations with Acquisition of Telefónica Ecuador

Millicom International Cellular S.A. has entered into a definitive agreement to acquire Telefónica’s operations in Ecuador for $380 million. The transaction is subject to regulatory approvals and customary closing conditions.

The fixed broadband segment has seen annual growth of 3.6%, while mobile subscriptions grew by 1.4%, despite recent economic volatility. Telefónica Ecuador serves approximately 4.8 million mobile subscribers in a fragmented competitive landscape.

According to recent census data, Ecuador has a population of approximately 18.5 million, with 66% living in urban areas and a median age of 32.4. The country operates under a dollarized monetary system and has shown signs of improving macroeconomic fundamentals. According to recent data, Ecuador’s fiscal deficit narrowed from 3.5% to 1.4% of GDP in one year, while international reserves increased by $2.4 billion.

The economy is supported by a $4 billion International Monetary Fund (IMF) facility and ongoing reform programs backed by the IMF and World Bank aimed at improving governance and private sector investment.

Analyst Lowers Rating Following Acquisition

Scotiabank analyst Andres Coello downgraded from Sector Outperform to Sector Perform and announced a $37 price target.

Which Analyst has the best track record to show on TIGO?

Analyst Mathieu Robilliard (BARCLAYS) currently has the highest performing score on TIGO with 4/5 (80%) price target fulfillment ratio. His price targets carry an average of $5.5 (18.03%) potential upside. Millicom International Cellular S.A. stock price reaches these price targets on average within 121 days.

Perpetua Resources Advances Project and Assurance Financing Plans

Perpetua Resources announced it completed two equity financing transactions totaling approximately $425 million. The first raised $325 million through a public offering, while the second generated $100 million via a concurrent private placement.

Perpetua indicated that these proceeds are intended to contribute to the equity component of a proposed $2 billion debt financing application currently under review by the Export-Import Bank of the United States (EXIM). If the EXIM application is approved, Perpetua projects closing on the debt facility in 2026. The combined funding initiatives are expected to support development of a project with an estimated construction cost of $2.2 billion.

In parallel, Perpetua is pursuing additional financing mechanisms, including up to $250 million through a proposed royalty or metal stream agreement. Perpetua is also seeking a $155 million financial guarantee to address construction-phase reclamation obligations.

Analyst Maintains Rating Amid Progress on Financing Plans

HC Wainwright & Co. analyst Heiko Ihle reiterated with a Buy rating and a $27.5 price target.

Which Analyst has the best track record to show on PPTA?

Analyst Lucas Pipes (B. RILEY) currently has the highest performing score on PPTA with 0/1 (0%) price target fulfillment ratio. His price targets carry an average of $16.62 (308.92%) potential upside.

FDA Sets PDUFA Target Date for Aquestive Therapeutics’ Anaphylaxis Drug Candidate

Aquestive Therapeutics has announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for Anaphylm, a sublingual film formulation of epinephrine intended for the treatment of Type 1 allergic reactions, including anaphylaxis.

The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026, and stated that it may convene an Advisory Committee meeting as part of the review process. According to the company, Anaphylm is intended to deliver epinephrine via a sublingual dissolvable film. In clinical studies conducted by the company, the product demonstrated rapid systemic absorption and reached therapeutic epinephrine levels within minutes. The product does not require refrigeration and is approximately the size of a credit card.

According to the Centers for Disease Control and Prevention, an estimated 33 million people in the United States have food allergies, including approximately 5.6 million children. Anaphylaxis, a severe and potentially life-threatening allergic reaction, accounts for roughly 200,000 emergency department visits annually in the U.S. Epinephrine remains the only FDA-approved first-line treatment for such reactions.

Research indicates that up to 60% of individuals at risk do not consistently carry epinephrine auto-injectors, often due to device bulk or fear of self-administration. Population-based studies estimate that as many as 5.1% of U.S. residents, over 17 million people, may experience anaphylaxis in their lifetime.

Analyst Reiterates Rating Following FDA Acceptance of Anaphylm NDA

HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating and $10 price target.

Which Analyst has the best track record to show on AQST?

Analyst Andreas Argyrides (OPPENHEIMER) currently has the highest performing score on AQST with 5/7 (71.43%) price target fulfillment ratio. His price targets carry an average of $4.19 (149.11%) potential upside. Aquestive Therapeutics stock price reaches these price targets on average within 259 days.